non-squamous non-small cell lung cancer non-squamous non-small cell lung cancer, pembrolizumab, PD-L1, carboplatin, pemetrexed
Conditions
Interventions
Group A: 200 mg of Pembro is intravenously infused over 30 minutes and more on day 1. Repeat the administration every 3 weeks as one cycle until the treatment cessation criteria are met. Upper limit o
Sponsors
Kogure Yoshihito
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Non-squamous non-small cell lung cancer (NSCLC) confirmed by histology or cytology. 2) Not received prior systemic treatment with stage III not eligible for radical radiotherapy, stage IV, or recurrent NSCLC. 3) PD-L1 TPS of 50% or more with 22C3 antibody. 4) With at least one measurable lesion based on RECIST 1.1. 5) Age of 20 years or older on the day of informed consent. 6) ECOG Performance Status 0-1. 7) Without activating mutation in EGFR or ALK chromosomal translocation. 8) Absence of severe impairments of major organs. 9) Life expectancy of 12 weeks or more from the treatment start date. 10) Prior to the study registration, able to provide written informed consent after a thorough explanation of the study content.
Exclusion criteria
Exclusion criteria: 1) Has symptomatic brainmetastasis with anti-edematic drugs such as steroids (exceeding 5mg prednisolone/day or equivalent) 2) Has a known sensitivity to any component of protocol therapy drug 3) Has symptomatic ascites or pleural effusion 4) Has active autoimmune disease 5) Is on chronic systemic steroids 6) Completed palliative radiotherapy within 7 days of the first dose of the treatment or Received radiation therapy to the lung that exceeds 30 Gy within 6 months of the first dose of the study treatment 7) Has a history of malignancy 8) Has an active infection or severe complications 9) Is expecting to conceive or father children within the projected duration of the study 10) Has known active Hepatitis B or C 11) not eligible in the opinion of the principal investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| objective response rate overall survival toxicity | — |
Contacts
Public ContactYoshihito Kogure
NHO Nagoya Medical Center
Outcome results
None listed